Stocktoria
Arcus Biosciences, Inc. RCUS
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2018-03-15
Arcus Biosciences, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -156.3% | -127.9% | -290.6% | -250.0% | 14.1% |
| Net margin | -142.9% | -109.7% | -262.4% | -238.4% | 13.8% |
| FCF margin | -196.0% | -68.2% | -282.1% | 385.7% | -73.6% |
| Return on assets | -31.0% | -24.6% | -28.0% | -19.9% | 3.3% |
| Return on equity | -55.9% | -58.4% | -66.5% | -40.6% | 6.3% |
| Debt / equity | 0.16× | 0.10× | 0.00× | — | — |
| Current ratio | 4.36 | 4.50 | 4.52 | 5.53 | 7.60 |
| Revenue growth | -4.3% | 120.5% | 4.5% | -70.8% | 391.0% |
Source: SEC EDGAR filings · CIK 0001724521 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.